Sanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rd
Rhea-AI Summary
Sanara MedTech (Nasdaq: SMTI) will present at the TD Cowen 46th Annual Health Care Conference in Boston. Management is scheduled to deliver a presentation on Tuesday, March 3, 2026 at approximately 9:10 a.m. ET.
Presentation materials and a live audio webcast will be posted to the company’s Investor Relations website prior to the presentation, and an archived replay will be available after the conference.
Positive
- None.
Negative
- None.
News Market Reaction – SMTI
On the day this news was published, SMTI gained 0.95%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SMTI fell 2.65% with mixed peer action: ANGO -1.35%, KMTS -2.64%, OSUR -1.79%, STXS -1.00%, while EMBC rose 1.50%, pointing to stock-specific pressure rather than a clear sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Prelim earnings, guidance | Positive | -2.3% | Preliminary Q4/FY 2025 results and 2026 revenue guidance above prior year. |
| Jan 07 | Vizient contract win | Positive | -2.0% | BIASURGE awarded Innovative Technology contract with Vizient purchasing network. |
| Dec 10 | OsStic development update | Positive | +3.3% | OsStic progress with FDA Breakthrough designation and strong preclinical data. |
| Nov 19 | Conference participation | Neutral | -8.8% | Announcement of presentation at Piper Sandler healthcare conference. |
| Nov 12 | Q3 2025 earnings | Negative | -24.7% | Q3 growth offset by large impairment and substantial discontinued losses. |
Recent fundamentally positive updates have often been met with negative price reactions, while major negative items aligned with sharp declines.
Over the past several months, Sanara reported strong growth and guidance, with FY 2025 revenue expected above $102M and 2026 guidance of $116M–$121M, yet shares fell after both earnings and a Vizient contract win. An OsStic™ progress update with FDA Breakthrough status saw a positive move. Conference participation in Dec 2025 coincided with a notable drop. The latest TD Cowen conference appearance fits this pattern of ongoing investor outreach amid volatile reactions to prior news.
Market Pulse Summary
This announcement highlights Sanara’s participation in a major healthcare conference, with a scheduled March 3 presentation and webcast for investors. It continues a pattern of active investor outreach following prior updates on growth, guidance, and product development. Investors may watch how management frames recent financial performance, pipeline milestones, and strategic priorities in these materials, and how that communication aligns with subsequent SEC filings and earnings results.
AI-generated analysis. Not financial advice.
FORT WORTH, TX, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that management will participate in the TD Cowen 46th Annual Health Care Conference, which is being held at the Boston Marriott Copley Place in Boston, MA from March 2 – 4, 2026. Management will deliver a presentation to investors on Tuesday, March 3 at approximately 9:10 a.m. Eastern Time.
The presentation materials for the conference will be posted to the Company’s investor relations website, https://ir.sanaramedtech.com/, prior to the presentation. A live audio webcast of the presentation will also be accessible under the “Events” section of the Company’s Investor Relations website at https://ir.sanaramedtech.com/. An archive of the webcast will be available for replay following the conference.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company’s products and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara’s products are primarily sold in the North American surgical tissue repair market. Sanara markets and distributes CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN® Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix and TEXAGEN® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expects,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, and the regulatory approval process. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Relations Contact:
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
FAQ
When will Sanara MedTech (SMTI) present at the TD Cowen Health Care Conference?
How can investors access Sanara MedTech (SMTI) presentation materials for the March 3, 2026 session?
Will there be a live webcast of Sanara MedTech's (SMTI) March 3, 2026 presentation?
Where will Sanara MedTech (SMTI) present in person during the TD Cowen conference?
Will Sanara MedTech (SMTI) provide an archived replay of the March 3, 2026 presentation?
What topics will Sanara MedTech (SMTI) cover during the March 3, 2026 investor presentation?
